Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2010 1
2011 2
2012 2
2013 5
2014 2
2015 1
2016 4
2017 3
2018 2
2022 1
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Burns KEA, Heels-Ansdell D, Thabane L, Kahn SR, Lauzier F, Mehta S, Ostermann M, Bhuptani P, Crowther MA, Finfer S, Cook DJ; PROTECT Investigators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Burns KEA, et al. Can J Anaesth. 2023 Jun;70(6):1008-1018. doi: 10.1007/s12630-023-02457-8. Epub 2023 Jun 13. Can J Anaesth. 2023. PMID: 37310606 Clinical Trial. English.
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. Barratt J, et al. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180506 Free PMC article.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Facilitating Hemostasis After Proximal Aortic Surgery: Results of The PROTECT Trial.
Khoynezhad A, DelaRosa J, Moon MR, Brinkman WT, Thompson RB, Desai ND, Malaisrie SC, Girardi LN, Bavaria JE, Reece TB; PROTECT Investigators. Khoynezhad A, et al. Ann Thorac Surg. 2018 May;105(5):1357-1364. doi: 10.1016/j.athoracsur.2017.12.013. Epub 2018 Jan 12. Ann Thorac Surg. 2018. PMID: 29337125 Clinical Trial.
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Motzer RJ, et al. J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13. J Clin Oncol. 2017. PMID: 28902533 Free PMC article. Clinical Trial.
The association between platelet transfusions and bleeding in critically ill patients with thrombocytopenia.
Arnold DM, Lauzier F, Albert M, Williamson D, Li N, Zarychanski R, Doig C, McIntyre L, Freitag A, Crowther M, Saunders L, Clarke F, Bellomo R, Qushmaq I, Lopes RD, Heels-Ansdell D, Webert K, Cook D; PROTECT Investigators, the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Arnold DM, et al. Res Pract Thromb Haemost. 2017 May 31;1(1):103-111. doi: 10.1002/rth2.12004. eCollection 2017 Jul. Res Pract Thromb Haemost. 2017. PMID: 30046678 Free PMC article.
Assessment of right ventricular function in acute pulmonary embolism.
Barrios D, Morillo R, Lobo JL, Nieto R, Jaureguizar A, Portillo AK, Barbero E, Fernandez-Golfin C, Yusen RD, Jiménez D; PROTECT investigators. Barrios D, et al. Am Heart J. 2017 Mar;185:123-129. doi: 10.1016/j.ahj.2016.12.009. Epub 2016 Dec 29. Am Heart J. 2017. PMID: 28267465
Erratum to: Risk factors for mortality in patients admitted to intensive care units with pneumonia.
Li G, Cook DJ, Thabane L, Friedrich JO, Crozier TM, Muscedere J, Granton J, Mehta S, Reynolds SC, Lopes RD, Lauzier F, Freitag AP, Levine MA; PROTECT Investigators for the Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Li G, et al. Respir Res. 2016 Oct 7;17(1):128. doi: 10.1186/s12931-016-0444-2. Respir Res. 2016. PMID: 27717370 Free PMC article. No abstract available.
Risk factors for mortality in patients admitted to intensive care units with pneumonia.
Li G, Cook DJ, Thabane L, Friedrich JO, Crozier TM, Muscedere J, Granton J, Mehta S, Reynolds SC, Lopes RD, Lauzier F, Freitag AP, Levine MA; PROTECT Investigators for the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Li G, et al. Respir Res. 2016 Jul 11;17(1):80. doi: 10.1186/s12931-016-0397-5. Respir Res. 2016. PMID: 27401184 Free PMC article. Clinical Trial.
Competing Risk Analysis for Evaluation of Dalteparin Versus Unfractionated Heparin for Venous Thromboembolism in Medical-Surgical Critically Ill Patients.
Li G, Cook DJ, Levine MAH, Guyatt G, Crowther M, Heels-Ansdell D, Holbrook A, Lamontagne F, Walter SD, Ferguson ND, Finfer S, Arabi YM, Bellomo R, Cooper DJ, Thabane L; PROTECT Investigators for the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Li G, et al. Medicine (Baltimore). 2015 Sep;94(36):e1479. doi: 10.1097/MD.0000000000001479. Medicine (Baltimore). 2015. PMID: 26356708 Free PMC article. Clinical Trial.
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.
Cook D, Arabi Y, Ferguson N, Heels-Ansdell D, Freitag A, McDonald E, Clarke F, Keenan S, Pagliarello G, Plaxton W, Herridge M, Karachi T, Vallance S, Cade J, Crozier T, Alves da Silva S, Costa Filho R, Brandao N, Watpool I, McArdle T, Hollinger G, Mandourah Y, Al-Hazmi M, Zytaruk N, Adhikari NK; PROTECT Research Coordinators; PROTECT Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Cook D, et al. Intensive Care Med. 2013 Dec;39(12):2115-25. doi: 10.1007/s00134-013-3074-x. Intensive Care Med. 2013. PMID: 24022796 Clinical Trial.
Prognostic significance of multidetector CT in normotensive patients with pulmonary embolism: results of the protect study.
Jiménez D, Lobo JL, Monreal M, Moores L, Oribe M, Barrón M, Otero R, Nauffal D, Rabuñal R, Valle R, Navarro C, Rodríguez-Matute C, Alvarez C, Conget F, Uresandi F, Aujesky DA, Yusen RD; PROTECT investigators. Jiménez D, et al. Thorax. 2014 Feb;69(2):109-15. doi: 10.1136/thoraxjnl-2012-202900. Epub 2013 Mar 22. Thorax. 2014. PMID: 23525079
Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illness.
Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, Heels-Ansdell D, Guyatt G, Walter SD, Davies A, Cook DJ; PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Arnold DM, et al. Thromb Res. 2013 Mar;131(3):204-9. doi: 10.1016/j.thromres.2012.12.005. Epub 2013 Jan 12. Thromb Res. 2013. PMID: 23317632 Clinical Trial.
Co-enrollment of critically ill patients into multiple studies: patterns, predictors and consequences.
Cook D, McDonald E, Smith O, Zytaruk N, Heels-Ansdell D, Watpool I, McArdle T, Matte A, Clarke F, Vallance S, Finfer S, Galt P, Crozier T, Fowler R, Arabi Y, Woolfe C, Orford N, Hall R, Adhikari NK, Ferland MC, Marshall J, Meade M; PROTECT Research Coordinators; PROTECT Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Cook D, et al. Crit Care. 2013 Jan 8;17(1):R1. doi: 10.1186/cc11917. Crit Care. 2013. PMID: 23298553 Free PMC article. Clinical Trial.
Rates and determinants of informed consent: a case study of an international thromboprophylaxis trial.
Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, Meade L, O'Callaghan N, Vallance S, Galt P, Rajbhandari D, Rocha M, Mehta S, Ferguson ND, Hall R, Fowler R, Burns K, Qushmaq I, Ostermann M, Heels-Ansdell D, Cook D; PROTECT Research Coordinators; PROTECT Investigators; Canadian Critical Care Trials Group; Australian, New Zealand Intensive Care Society Clinical Trials Group. Smith OM, et al. J Crit Care. 2013 Feb;28(1):28-39. doi: 10.1016/j.jcrc.2012.08.005. Epub 2012 Oct 22. J Crit Care. 2013. PMID: 23089679
Research ethics board approval for an international thromboprophylaxis trial.
Lutz K, Wilton K, Zytaruk N, Julien L, Hall R, Harvey J, Skrobik Y, Vlahakis N, Meade L, Matte A, Meade M, Burns K, Albert M, Cash BB, Vallance S, Klinger J, Heels-Ansdell D, Cook D; PROTECT Investigators in collaboration with the CCCTG and ANZICS-CTG. Lutz K, et al. J Crit Care. 2012 Jun;27(3):225-31. doi: 10.1016/j.jcrc.2011.12.012. Epub 2012 Feb 4. J Crit Care. 2012. PMID: 22305662
Dalteparin versus unfractionated heparin in critically ill patients.
PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group; Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, et al. N Engl J Med. 2011 Apr 7;364(14):1305-14. doi: 10.1056/NEJMoa1014475. Epub 2011 Mar 22. N Engl J Med. 2011. PMID: 21417952 Free article. Clinical Trial.
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Massie BM, et al. N Engl J Med. 2010 Oct 7;363(15):1419-28. doi: 10.1056/NEJMoa0912613. N Engl J Med. 2010. PMID: 20925544 Free article. Clinical Trial.
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study.
Cook DJ, Rocker G, Meade M, Guyatt G, Geerts W, Anderson D, Skrobik Y, Hebert P, Albert M, Cooper J, Bates S, Caco C, Finfer S, Fowler R, Freitag A, Granton J, Jones G, Langevin S, Mehta S, Pagliarello G, Poirier G, Rabbat C, Schiff D, Griffith L, Crowther M; PROTECT Investigators; Canadian Critical Care Trials Group. Cook DJ, et al. J Crit Care. 2005 Dec;20(4):364-72. doi: 10.1016/j.jcrc.2005.09.010. J Crit Care. 2005. PMID: 16310609 Clinical Trial.